Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.36 |
| ▸ | FDPS | P14324 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9196272 | 1.00 | PAOX (0.36) | PAOXFDPSDGAT1CPB2MEN1 | |
| SCHEMBL20496960 | 1.00 | PAOX (0.36) | PAOXFDPSDGAT1CPB2MEN1 | |
| SCHEMBL7802855 | 0.98 | DGAT1 (0.36) | PAOXFDPSDGAT1CPB2MEN1 | |
| SCHEMBL3294151 | 0.92 | DGAT1 (0.38) | PAOXFDPSDGAT1LMNATDP1 | |
| SCHEMBL19065775 | 0.91 | DGAT1 (0.44) | PAOXFDPSDGAT1TDP1 | |
| SCHEMBL7209803 | 0.91 | PAOX (0.42) | PAOXMEN1LMNAALOX15RECQL | |
| SCHEMBL7203559 | 0.91 | PAOX (0.42) | PAOXMEN1LMNAALOX15RECQL | |
| SCHEMBL7204574 | 0.91 | PAOX (0.42) | PAOXMEN1LMNAALOX15RECQL | |
| SCHEMBL7205258 | 0.91 | PAOX (0.42) | PAOXMEN1LMNAALOX15RECQL | |
| SCHEMBL4617700 | 0.89 | ODC1 (0.37) | PAOXFDPSDGAT1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3192529-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2020-03-25 | — | — | EP | disclosed |
| EP-3485912-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3192529-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2416804-B1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | FAULSTICH HEINZ DR (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-03-31 | — | — | US | disclosed |
| US-9233173-B2 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2012-04-26 | — | — | US | disclosed |
| EP-2416804-A2 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | Faulstich, Heinz, Dr. (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115629-A2 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2010-10-14 | — | — | WO | disclosed |
| EP-0314042-A2 | Novel copolymers and superoxide dismutase modified with said copolymers | KURARAY CO., LTD. (JP) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100161-A1 | Amatoxin-Armed Therapeutic Cell Surface Binding Components Designed for Tumour Therapy | ANTXR2, TNFSF10, ANXA5 | PAOX 3762/4885FDPS 3781/4885DGAT1 2256/4885 |
| US-20160089450-A1 | AMATOXIN-ARMED THERAPEUTIC CELL SURFACE BINDING COMPONENTS DESIGNED FOR TUMOUR THERAPY | ANTXR2, TNFSF10, ANXA5 | PAOX 3762/4885FDPS 3781/4885DGAT1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.